Capricor Therapeutics, Inc.
CAPR · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 2.55M | -19.27M | -29.70M | -29.02M | -1.18 |
| 2023 FY | 25.18M | -11.27M | -24.08M | -22.29M | -0.83 |
| 2024 FY | 22.27M | -27.70M | -42.56M | -40.47M | -1.15 |
| 2025 FY | — | — | -108.14M | -105.04M | -2.26 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 50.09M | 38.31M | 9.60M | 5.94M | 11.79M |
| 2023 FY | 58.73M | 36.13M | 14.69M | 5.61M | 22.60M |
| 2024 FY | 170.48M | 25.02M | 11.29M | 4.83M | 145.46M |
| 2025 FY | 355.95M | 50.16M | 287.85M | 17.94M | 305.79M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 4.92M | -3.36M | 1.56M | — | -25.28M |
| 2023 FY | -25.60M | -2.05M | -27.64M | — | 5.09M |
| 2024 FY | -40.00M | -1.54M | -41.53M | — | -3.41M |
| 2025 FY | -69.81M | -2.90M | -72.72M | — | 276.56M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 94.77M | 91.11M | — | — | — |
| 2023 FY | 130.94M | 121.86M | — | — | — |
| 2024 FY | 486.02M | 479.56M | — | — | — |
| 2025 FY | 1.34B | 1.07B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | -22.05M | -27.72M | -25.91M | -0.57 |
| 2025 Q3 | — | -20.36M | -26.28M | -24.57M | -0.54 |
| 2025 Q4 | — | — | -29.16M | -30.17M | -0.62 |
| 2026 Q1 | — | — | -36.77M | -33.94M | -0.59 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 133.57M | 28.59M | 23.24M | 4.42M | 104.98M |
| 2025 Q3 | 126.44M | 42.57M | 19.51M | 17.92M | 83.87M |
| 2025 Q4 | 355.95M | 50.16M | 287.85M | 17.94M | 305.79M |
| 2026 Q1 | 326.28M | 47.58M | 105.42M | 21.12M | 278.70M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -20.12M | -1.45M | -21.57M | — | -5.55M |
| 2025 Q3 | -19.69M | -4.01M | -23.70M | — | -3.73M |
| 2025 Q4 | -23.57M | -5.12M | -28.69M | — | 268.34M |
| 2026 Q1 | -29.25M | -10.75M | -40.00M | — | -182.43M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 453.89M | 435.07M | — | — | — |
| 2025 Q3 | 329.61M | 328.02M | — | — | — |
| 2025 Q4 | 1.41B | 1.14B | — | — | — |
| 2026 Q1 | 1.75B | 1.66B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |